These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 32481570)

  • 1. Enhancing the Efficacy of CAR T Cells in the Tumor Microenvironment of Pancreatic Cancer.
    Henze J; Tacke F; Hardt O; Alves F; Al Rawashdeh W
    Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32481570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic Redirection of T Cells for the Treatment of Pancreatic Cancer.
    Ali AI; Oliver AJ; Samiei T; Chan JD; Kershaw MH; Slaney CY
    Front Oncol; 2019; 9():56. PubMed ID: 30809507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast Activation Protein (FAP)-Targeted CAR-T Cells: Launching an Attack on Tumor Stroma.
    Bughda R; Dimou P; D'Souza RR; Klampatsa A
    Immunotargets Ther; 2021; 10():313-323. PubMed ID: 34386436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Target selection of CAR T cell therapy in accordance with the TME for solid tumors.
    Liu B; Yan L; Zhou M
    Am J Cancer Res; 2019; 9(2):228-241. PubMed ID: 30906625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric Antigen Receptors for the Tumour Microenvironment.
    Habib R; Nagrial A; Micklethwaite K; Gowrishankar K
    Adv Exp Med Biol; 2020; 1263():117-143. PubMed ID: 32588326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Potential of CAR T Cell Therapy in Pancreatic Cancer.
    Akce M; Zaidi MY; Waller EK; El-Rayes BF; Lesinski GB
    Front Immunol; 2018; 9():2166. PubMed ID: 30319627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
    Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success.
    Long KB; Young RM; Boesteanu AC; Davis MM; Melenhorst JJ; Lacey SF; DeGaramo DA; Levine BL; Fraietta JA
    Front Immunol; 2018; 9():2740. PubMed ID: 30559740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy.
    Hawkins ER; D'Souza RR; Klampatsa A
    Biologics; 2021; 15():95-105. PubMed ID: 33883875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-Mesothelin CAR T cell therapy for malignant mesothelioma.
    Castelletti L; Yeo D; van Zandwijk N; Rasko JEJ
    Biomark Res; 2021 Feb; 9(1):11. PubMed ID: 33588928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Metabolism Toolbox for CAR T Therapy.
    Xu X; Gnanaprakasam JNR; Sherman J; Wang R
    Front Oncol; 2019; 9():322. PubMed ID: 31114756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The next wave of cellular immunotherapies in pancreatic cancer.
    Yeo D; Giardina C; Saxena P; Rasko JEJ
    Mol Ther Oncolytics; 2022 Mar; 24():561-576. PubMed ID: 35229033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.
    Mohammed S; Sukumaran S; Bajgain P; Watanabe N; Heslop HE; Rooney CM; Brenner MK; Fisher WE; Leen AM; Vera JF
    Mol Ther; 2017 Jan; 25(1):249-258. PubMed ID: 28129119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Chimeric Antigen Receptor Design for Solid Tumors.
    Wang Y; Luo F; Yang J; Zhao C; Chu Y
    Front Immunol; 2017; 8():1934. PubMed ID: 29312360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment.
    Scarfò I; Maus MV
    J Immunother Cancer; 2017; 5():28. PubMed ID: 28331617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric antigen receptor modified T-cells for cancer treatment.
    Han X; Wang Y; Han WD
    Chronic Dis Transl Med; 2018 Dec; 4(4):225-243. PubMed ID: 30603741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAR-T cell therapy in melanoma: A future success story?
    Simon B; Uslu U
    Exp Dermatol; 2018 Dec; 27(12):1315-1321. PubMed ID: 30288790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cells.
    Yazdanifar M; Zhou R; Mukherjee P
    Curr Trends Immunol; 2016; 17():95-115. PubMed ID: 28659689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.